Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Allbirds IncTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Allbirds Inc trades at $2.59 (market cap $30.00M), while Ginkgo Bioworks Holdings Inc trades at $7.44 (market cap $505.73M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 16.9× Allbirds Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.

BIRDDNA
Market Cap
$30.00M$505.73M
Sector
Consumer CyclicalHealth
52-Week High
$16.99$16.14
52-Week Low
$2.21$5.48
Enterprise Value
$48.86M$607.68M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD trades at $2.58, up 1.98% today, amid a strategic pivot from footwear to AI infrastructure, rebranding as Smartbird. Despite negative profitability and cash burn, the stock shows bullish technical signals and surged on recent leadership changes. Revenue has declined from $298M in 2022 to $152M in 2025, with net losses persisting but improving from -$152M to -$77M over the period.

Outlook hinges on successful AI transition, but high execution risk and sustained losses warrant caution. Analysts are mostly neutral, with 79% hold ratings. The stock offers speculative upside if new strategy gains traction, yet faces significant financial and competitive headwinds.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Returns comparison

Trailing returns across standard periods

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA